Thanks for joining DividendStocks.com, the daily newsletter built for dividend and income investors like you. We’re thrilled to have you on board and can’t wait to help you discover the best dividend opportunities out there. Before we can start sending your daily insights, please take a quick moment to confirm your subscription: Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Why wait? Let’s get your dividend journey started! Click Here to Start Discovering Top Income-Generating Stocks See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Media 3 Stocks You'll Wish You Bought Before 2026Written by Chris Markoch. Published 12/3/2025. 
Key Points - These three up-and-coming stocks have delivered triple-digit gains in 2025 and continue to show strong momentum.
- Key catalysts—including clinical milestones, revenue acceleration, and consumer demand—suggest more upside ahead.
- Analysts stay optimistic, with price targets suggesting possible double- or triple-digit gains from current levels.
Many investors have profited from the artificial intelligence (AI) trade in 2025. But there have been several up-and-coming stocks in other sectors that posted impressive gains this year. The three stocks in this article are still small caps; the largest market cap is just over $4 billion. However, they've made strong moves and illustrate the idea that time in the market is often better than trying to time it. Turn your "dead money" into $306+ monthly (starting this month)
I've been tracking a financial revolution that most people don't even know exists yet.
With 10X less money than what financial advisors say you need!
This is a new type of investment you can buy with one click in your brokerage account. Collect the next payout now → Of course, if investors could see the future with absolute clarity, investing would be easy. The future is rarely clear, and a bullish outcome is not guaranteed. Still, the charts speak for themselves: investors who bought these stocks and had the patience to hold through rough patches are reaping the benefits today. Better still, the stocks may not be done moving higher. Biotech Breakthrough: A Small Cap With a Big 2026 FDA Catalyst Celcuity Inc. (NASDAQ: CELC) is a clinical-stage biotechnology company that recently delivered positive data for its first-in-class PI3K/mTOR inhibitor targeting HR+/HER2- metastatic breast cancer. The company's pivotal Phase 3 VIKTORIA trial is underway, and some investors believe the company could receive U.S. Food & Drug Administration (FDA) approval in 2026. Investors have been front-running those expectations, pushing CELC stock up more than 660%, with nearly all of those gains occurring since the end of July. At $99.30 at the time of writing, the stock sits within roughly 3% of its consensus price target. Jefferies raised its price target on Dec. 2 to $134 from $108. The biggest risk for investors is the cost of commercialization. In its most recent earnings report, Celcuity showed a strengthened balance sheet with $455 million in cash, cash equivalents, and short-term investments — up about 72% year-over-year (YOY). Management says that should be sufficient to fund operations until commercialization begins. Fintech Disruptor Turning Revenue Growth Into Real Momentum At a time when many banks offer less to consumers, it's easy to make the case for Dave Inc. (NASDAQ: DAVE), a Los Angeles-based fintech known for its Dave app. The Dave app provides affordable, transparent financial tools that help users — many living paycheck to paycheck — avoid overdraft fees, budget better, and access short-term cash when needed. The company recently reported a 64% YOY increase in revenue and an 85% beat in adjusted earnings per share (EPS). DAVE stock is up about 120% in 2025, and analysts see more upside. At roughly $208.24, the consensus price target is $304.25 — more than 46% higher. Some investors may worry about the company's forward price-to-earnings (P/E) ratio of around 119x. However, analysts forecast earnings growth north of 117% over the next 12 months, which could help justify that valuation if the company continues to deliver. Resale Retail Winner Riding a Massive Consumer Shift It's been another tough year for consumer staples stocks, but ThredUp Inc. (NASDAQ: TDUP) has been a notable exception. TDUP stock is up more than 430% in 2025, despite a roughly 29% sell-off in the three months through Dec. 1. The company operates as an online consignment store, making it well positioned as many consumer budgets remain stretched. The thrift and resale market was a $49 billion industry in 2024 and is expected to grow to $74 billion by 2029. TDUP is the smallest of the three stocks on this list, and short interest above 17% indicates active trading. The company's Q3 report showed strong YOY revenue growth and, importantly, a record number of new buyer acquisitions plus a 37% YOY increase in orders. Admittedly, this could be a shorter-term trade. But younger consumers — ThredUp's core market — may remain budget-conscious for some time, which helps explain analysts' consensus price target of $12.50, roughly 68% above the Dec. 1 close.
| 
